UCB presents Bimzelx data as UCB stock trades at EUR 201.20

Published on 10/07/2026 at 09:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock costs EUR 201.20 on October 7, 2026 after EUR 202.00, down 0.40 percent. First-half revenue rose 22.50 percent to EUR 4.27 billion.

Architektur-Render eines geschwungenen Glasgebäudes mit Reflexionsbecken und begrünter Umgebung — UCB S.A. (BE0003739530) symbolisiert durch elegantes Architektur-Render eines modernen Biopharma-Hauptsitzes mit Glasfassade, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 201.20 at Lang & Schwarz on October 7, 2026 at 9:24 a.m. CEST, down 0.40 percent versus the prior close of EUR 202.00. On September 30, 2026, UCB presented new Bimzelx data at the European Academy of Dermatology and Venereology Congress in Vienna.

Earlier treatment shows a measurable gap

The company reported that 47.40 percent of patients with the shortest time since diagnosis achieved complete inflammatory lesion resolution after three years, measured by IHS4-100. The corresponding figure for patients with the longest time since diagnosis was 33.30 percent, a 14.10 percentage-point difference.

Biologic-naive patients also recorded complete draining tunnel resolution at three years in 67.30 percent of cases, compared with 47.70 percent among biologic-experienced patients. The figures came from post-hoc analyses of the BE HEARD trials, so the comparison describes an observed difference rather than proof that earlier treatment caused the outcome.

Bimzelx remains the central growth driver

Ideal Investor reported first-half 2026 revenue of EUR 4.27 billion, up 22.50 percent year over year, with adjusted EBITDA of EUR 1.69 billion and a 40.70 percent adjusted EBITDA margin. UCB's investor materials list Bimzelx sales of EUR 1.52 billion in the first half of 2026 and peak sales guidance above EUR 7.00 billion.

The commercial case therefore rests on both adoption and durability. Bimzelx was associated with complete resolution of all tunnels in 30.70 percent of patients after one year, versus 14.50 percent at baseline, while UCB presented 23 abstracts across its portfolio at EADV.

UCB stock stays close to its yearly low

The finance quote for UCB.BR showed a EUR 198.75 to EUR 289.50 52-week range and a market capitalization of EUR 38.3 billion as of October 7, 2026. The Lang & Schwarz price was EUR 3.50 above that quoted yearly low, while the company remained exposed to patent and reimbursement risks described in its investor materials.

UCB is listed on Euronext Brussels under ticker UCB. The combination of fast first-half growth and a concentrated Bimzelx thesis makes the post-hoc evidence useful for assessing execution, but the study design keeps the clinical comparison interpretive rather than definitive. The further course of trading is shown by the continuously updated real-time quote of UCB stock.